Aktive Positionen von Pablo Umaña
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2000 | - |
| Gründer | 01.09.2000 | - |
Karriereverlauf von Pablo Umaña
Ehemalige bekannte Positionen von Pablo Umaña
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ROCHE HOLDING AG | Corporate Officer/Principal | - | - |
Statistik
International
| Schweiz | 3 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Health Technology |
- Börse
- Insiders
- Pablo Umaña
- Erfahrung
